117087-17-9

Basic information

• Product Name: 5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane
• Synonyms: 5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane
• CAS NO: 117087-17-9
• Molecular Weight: 236.311
• Mol File: 117087-17-9.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane(117087-17-9)
• EPA Substance Registry System: 5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane(117087-17-9)

Safety Data

• Hazardous Substances Data: 117087-17-9(Hazardous Substances Data)

Usage

General Description

5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane is a chemical compound that is composed of a dioxane ring with a benzyloxy group attached to one of the carbon atoms. It also contains two methyl groups on the dioxane ring. 5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane is commonly used as a solvent in various chemical reactions due to its ability to dissolve a wide range of substances. It is also known for its stability and low reactivity, making it a suitable option for many industrial applications. Additionally, the presence of the benzyloxy group provides a unique functionality that can be utilized in the synthesis of pharmaceuticals and other organic compounds.

Upstream product

• 4728-12-5 2,2-dimethyl-5-hydroxymethyl-1,3-dioxane 
• 7732-18-5 water 
• 100-39-0 benzyl bromide 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 138435-88-8 3-Acetoxy-2-(acetoxymethyl)-1-(benzyloxy)propane 
• 138435-90-2 C₁₃H₁₈O₄ 
• 138435-91-3 (S)-3-(benzyloxy)-2-(hydroxymethyl)propyl acetate 
• 1394849-49-0 (S)-3-(benzyloxy)-2-[(mesyloxy)methyl]propyl acetate 
• 1394849-50-3 C₂₁H₂₁NO₅ 
• 1394849-51-4 (S)-3-(benzyloxy)-2-{[bis(tert-butoxycarbonyl)amino]-methyl}propyl acetate 
• 1394849-52-5 (S)-3-(benzyloxy)-2-({[tert-butyl(dimethyl)silyl]oxy}-methyl)propyl acetate 
• 1394849-53-6 (R)-3-(benzyloxy)-2-({[tert-butyl(dimethyl)silyl]oxy}-methyl)propan-1-ol 
• 1394849-54-7 (R)-3-(benzyloxy)-2-({[tert-butyl(dimethyl)silyl]oxy}-methyl)propyl methanesulfonate 
• 1394849-55-8 di-tert-butyl (R)-2-[3-(Benzyloxy)-2-({[tert-butyl-(dimethyl)silyl]oxy}methyl)propyl]-2-imidodicarbonate 
• 1394849-56-9 di-tert-butyl (S)-2-[3-(benzyloxy)-2-(hydroxymethyl)-propyl]-2-imidodicarbonate 
• 1394849-30-9 (R)-3-amino-2-[(benzyloxy)methyl]propan-1-ol monohydrochloride 
• 1394849-60-5 (S)-3-amino-2-[(benzyloxy)methyl]propan-1-ol monohydrochloride 
• 1122410-44-9 [3-azido-2-(azidomethyl)propoxy]methyl benzene 

Relevant articles and documents

Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs

Two new series of symmetric acyclic nucleoside bisphosphonates (ANbPs) have been synthesised as potential inhibitors of the Plasmodium falciparum (Pf) and vivax (Pv) 6-oxopurine phosphoribosyltransferases. The structural variability between these symmetric ANbPs lies in the number of atoms in the two acyclic linkers connecting the N9 atom of the purine base to each of two phosphonate groups and the branching point of the acyclic moiety relative to the purine base, which occurs at either the alpha or beta positions. Within each series, six different 6-oxopurine bases have been attached. In general, the ANbPs with either guanine or hypoxanthine have lower Ki values than for those containing either the 8-bromo or 7-deaza 6-oxopurine bases. The lowest Ki values obtained for the two parasite enzymes were 0.1?μM (Pf) and 0.2?μM (Pv) for this series of compounds. Two phosphoramidate prodrugs of these inhibitors exhibited antimalarial activity against Pf in infected erythrocyte cell culture with IC50 values of 0.8 and 1.5?μM. These two compounds exhibited low cytotoxicity in human A549 cells having CC50 values of >300?μM resulting in an excellent selectivity index.

MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.